RSSL, a pharmaceutical contract research organization, has announced a new Innovation Hub—a dedicated platform to help small- and medium-sized biotech organizations de-risk and accelerate the development of cutting-edge products.
RSSL’s Innovation Hub aims to be a supportive ecosystem for early-stage biotech companies, providing a range of tailored services to help them navigate their journeys from concept to commercialization.
According to the company, by working with RSSL, clients can access on-site commercial laboratory space, with equipment and instrumentation available for use. They will also be able to benefit from RSSL’s expertise, project management experience, and network of industry contacts to support their product development.
About the Platform
The platform comprises four different models that will allow clients to collaborate with RSSL on a flexible basis depending on their needs. For each model, clients will have a dedicated account manager to oversee operations and serve as their main point of contact. The four models include:
- Innovate: Clients have access to laboratory space and equipment, with the option to utilize RSSL’s range of services as required.
- Forge: Clients have access to laboratory space, equipment, and services, plus consultancy in key areas such as training and regulatory compliance.
- Launchpad: A model designed for clients looking for support with commercial development.
- 360: A model providing clients with full-service support across the entire development pipeline, from initial concept to commercial manufacturing.
The launch of RSSL’s Innovation Hub is a key component of its long-term expansion strategy that will see the company implement several initiatives to increase its operational capacity and breadth of services. These initiatives will build on the recent opening of its new analytical testing facility, which has added 26,000 sq. ft. of working laboratory space. They will also play a crucial role in supporting its plans to double the number of members within its scientific team over the next three years.
Jacinta George, Managing Director, RSSL said: “Our goal is to drive vital research and support innovation across the entire life science sector. With the new Innovation Hub, we are providing start-ups, spin-outs, and other early-stage biotech organizations with dedicated laboratory space and specialist expertise to fast-track their development programs. We know how difficult it can be for emerging companies to access commercial facilities, so we’re incredibly proud to be providing our support. Through this collaboration, we’re excited to help them develop the next wave of ground-breaking products — from life-changing cell and gene therapies to next-generation vaccines and medical devices.”
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
